Liraglutide’s Future Uncertain: Panel Voices Concern Over Cancer And CV Risk

Approval of Novo Nordisk's Victoza (liraglutide) for type 2 diabetes hinges on FDA's comfort with a safety database lacking on two fronts, an agency panel said April 2

More from Archive

More from Pink Sheet